Gut Permeability Protocol

Overview

Intestinal permeability — commonly referred to as "leaky gut" — describes a state where the tight junctions between intestinal epithelial cells become compromised, allowing molecules, bacteria, and toxins to pass through the gut barrier into the bloodstream. This triggers systemic immune activation and chronic low-grade inflammation that can manifest as digestive symptoms, food sensitivities, brain fog, joint pain, skin conditions, and autoimmune flares.

The gut barrier is maintained by a complex system of tight junction proteins (occludin, claudins, zonulin), a mucus layer, antimicrobial peptides, and immune surveillance (secretory IgA). Disruption can result from chronic stress, NSAIDs, alcohol, processed food diets, dysbiosis, infections, and inflammatory conditions.

This protocol targets gut permeability through three complementary mechanisms: oral BPC-157 for direct mucosal healing and tight junction support, KPV peptide for intestinal anti-inflammatory effects, and L-glutamine as the primary fuel source for enterocytes (intestinal epithelial cells). For broader gut health approaches, see the Gut Healing Protocol and Gut Microbiome Protocol.

Compounds Involved

BPC-157 Oral

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide derived from a protein found in human gastric juice. While much of the BPC-157 discussion in the peptide community focuses on injectable use for musculoskeletal injuries, its origin as a gastric peptide makes oral administration particularly relevant for gut applications.

Preclinical research has demonstrated that oral BPC-157 promotes gastric and intestinal mucosal healing, protects against NSAID-induced gut damage, modulates the nitric oxide (NO) system, and supports blood vessel formation in damaged tissue. Its stability in gastric acid (unlike most peptides) is a distinguishing feature that enables effective oral dosing.

For musculoskeletal applications of BPC-157, see the Return to Sport Protocol and Tendon Repair Protocol.

KPV

KPV is a C-terminal tripeptide fragment (Lys-Pro-Val) of alpha-melanocyte-stimulating hormone (alpha-MSH). It retains the potent anti-inflammatory properties of the parent hormone without the melanocortin receptor-mediated effects on pigmentation. KPV has been studied for its ability to inhibit NF-kB activation (a master regulator of inflammatory gene expression), reduce pro-inflammatory cytokine production in intestinal epithelial cells, promote mucosal healing in colitis models, and cross cell membranes to exert intracellular anti-inflammatory effects.

KPV is particularly relevant for gut permeability driven by inflammatory bowel conditions, as it targets the inflammatory cascade at a fundamental level.

L-Glutamine

L-Glutamine is the most abundant amino acid in the body and the primary metabolic fuel for enterocytes. During periods of stress, illness, or intensive exercise, glutamine demand can outstrip supply, leading to enterocyte energy deficit and subsequent barrier dysfunction. Supplemental glutamine provides direct substrate for intestinal cell energy production, supports tight junction protein expression, promotes mucus production, and serves as a precursor for glutathione (the primary intracellular antioxidant).

Protocol Structure

Phase 1: Remove and Assess (Weeks 1–2)

Before introducing repair compounds, identify and remove ongoing sources of barrier disruption.

Identify triggers:

• Discontinue or minimize NSAIDs (a major cause of intestinal permeability)
• Reduce or eliminate alcohol
• Identify and eliminate food sensitivities (common culprits: gluten, dairy, processed seed oils)
• Address chronic stress through lifestyle modification

Baseline testing (optional but recommended):

• Lactulose-mannitol intestinal permeability test
• Zonulin (serum or stool) — a biomarker of tight junction opening
• Comprehensive stool analysis (GI-MAP or similar) for dysbiosis assessment
• Food sensitivity panel (IgG/IgA-based)
• Secretory IgA (stool) — mucosal immune status

See Blood Work Monitoring for general guidance.

Phase 2: Foundation Repair (Weeks 3–8)

Begin the core repair protocol.

Daily protocol:

Dietary support:

• Bone broth (rich in glycine, proline, and glutamine) — 1–2 cups daily
• Prebiotic fibers (gradually introduced) — feed beneficial gut bacteria
• Fermented foods (sauerkraut, kimchi, kefir) — if tolerated
• Adequate protein (1.2–1.6 g/kg) for amino acid substrate

Phase 3: KPV Addition (Weeks 5–12)

Add KPV for targeted anti-inflammatory support, overlapping with the ongoing Phase 2 compounds.

Combined daily protocol:

Phase 4: Maintenance (Weeks 13+)

After the initial repair phase, transition to a maintenance protocol.

KPV can be discontinued after the initial 6–8 week course unless inflammatory symptoms persist. BPC-157 and glutamine can be continued long-term at maintenance doses or cycled (8 weeks on, 4 weeks off). See Peptide Cycling.

Oral BPC-157 Administration

Unlike most peptides that are degraded by stomach acid, BPC-157 demonstrates remarkable stability in the gastrointestinal environment — consistent with its origin as a gastric peptide.

Administration options:

• Capsule: Encapsulated BPC-157 powder taken with water on an empty stomach
• Sublingual: Dissolved under the tongue for partial absorption through the oral mucosa
• Direct oral: Dissolved in a small amount of water and swallowed

Empty stomach administration is preferred (at least 30 minutes before food or 2 hours after) to minimize interaction with food proteins and digestive enzymes.

Monitoring Progress

• Symptom tracking: Daily log of digestive symptoms (bloating, gas, stool consistency, food tolerance) using a 1–10 scale
• Repeat testing: If baseline permeability testing was performed, repeat at weeks 8–12 to assess improvement
• Food reintroduction: After 8+ weeks of the repair protocol, cautiously reintroduce eliminated foods one at a time, monitoring for symptom recurrence
• Stool quality: Bristol Stool Chart tracking can provide objective assessment of digestive function changes

Important Considerations

• Underlying conditions first: Celiac disease, Crohn's disease, and other diagnosed GI conditions require proper medical management. This protocol is complementary, not a replacement.
• Die-off reactions: If gut dysbiosis is present, antimicrobial interventions combined with permeability repair can produce temporary symptom worsening as pathogenic organisms are disrupted. This typically resolves within 1–2 weeks.
• Slow dietary changes: Rapid introduction of high-fiber and fermented foods can worsen symptoms in a compromised gut. Increase gradually.
• Gut-brain connection: Intestinal permeability is strongly linked to brain fog, mood changes, and cognitive issues through the gut-brain axis. Improvements in gut barrier function often correlate with cognitive improvements. See the Brain Fog Protocol.
• Quality: Oral peptides must be manufactured to high purity standards. See Purity and Testing.

Disclaimer

This article is for educational and informational purposes only. It does not constitute medical advice, and no therapeutic claims are made. Peptide research is ongoing, and individual outcomes may vary. Consult a qualified healthcare professional before beginning any peptide protocol. All compounds discussed are intended for research purposes.